Kronos Bio (NASDAQ:KRON) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Kronos Bio (NASDAQ:KRON) released its quarterly earnings results on Tuesday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13), Zacks reports. Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%. The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $1.00 million.

Kronos Bio Trading Down 1.7 %

Shares of KRON stock opened at $0.93 on Wednesday. The firm has a 50-day moving average price of $0.98 and a 200 day moving average price of $0.96. Kronos Bio has a twelve month low of $0.69 and a twelve month high of $1.60. The company has a market capitalization of $56.26 million, a price-to-earnings ratio of -0.65 and a beta of 1.79.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.